Please try another search
For the fiscal year ended 31 December 2018, Osiris Therapeutics, Inc. revenues increased 21% to $142.8M. Net income before extraordinary items increased from $3.6M to $36.5M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income benefited from General and administrative decrease of 11% to $19.6M (expense), Other income (expense).
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Revenue | 40.82 | 36.49 | 33.88 | 31.63 |
Gross Profit | 31.02 | 26.68 | 24.2 | 22.78 |
Operating Income | 6.23 | 3.96 | 2.17 | -2.5 |
Net Income | 32.53 | 4.21 | 2.48 | -2.32 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Total Assets | 101.5 | 84.7 | 79.83 | 78.58 |
Total Liabilities | 22.97 | 38.84 | 38.15 | 39.64 |
Total Equity | 78.53 | 45.86 | 41.68 | 38.93 |
Period Ending: | Dec 31, 2018 | Sep 30, 2018 | Jun 30, 2018 | Mar 31, 2018 |
---|---|---|---|---|
Period Length: | 12 Months | 9 Months | 6 Months | 3 Months |
Cash From Operating Activities | 7.3 | 13.02 | 4.91 | 0.34 |
Cash From Investing Activities | 5.97 | 15.56 | 15.09 | -0.06 |
Cash From Financing Activities | 0.01 | 0 | 0 | 0 |
Net Change in Cash | 13.29 | 28.58 | 19.99 | 0.28 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review